Pancreatic Cancer Research

ResearcherSeoul National UniversityNo recent work listed

Seock‐Ah Im

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-5396-6533; OpenAlex author ID A5069050806. Sources: ClinicalTrials.gov.

Their work

Papers
10
Trials
2 (principal investigator on 2)
Grants
0
Labs led
0
Collaborators
17
Papers, trials and grants by year

2004: 2 trials · 2005: none · 2006: none · 2007: none · 2008: none · 2009: none · 2010: none · 2011: 1 paper · 2012: 1 paper · 2013: none · 2014: 1 paper · 2015: 2 papers · 2016: 4 papers · 2017: none · 2018: none · 2019: none · 2020: none · 2021: 1 paper

Papers 10

  1. Phase II Trial of Postoperative Adjuvant Gemcitabine and Cisplatin Chemotherapy Followed by Chemoradiotherapy with Gemcitabine in Patients with Resected Pancre… Co-author DOI 10.4143/crt.2020.928↗
  2. More Accurate Prediction of Metastatic Pancreatic Cancer Patients' Survival with Prognostic Model Using Both Host Immunity and Tumor Metabolic Activity. Co-author DOI 10.1371/journal.pone.0145692↗
  3. Outcome Analysis of Chemoradiation in Unresectable Pancreatic Cancer Focusing on Treatment Sequencing Strategy. Co-author DOI 10.21873/anticanres.11125↗
  4. The Impact of Diabetes Mellitus and Metformin Treatment on Survival of Patients with Advanced Pancreatic Cancer Undergoing Chemotherapy. Co-author DOI 10.4143/crt.2014.292↗
  5. Concurrent Chemoradiotherapy Versus Chemotherapy Alone for Unresectable Locally Advanced Pancreatic Cancer: A Retrospective Cohort Study. Co-author DOI 10.4143/crt.2015.226↗
  6. Skeletal Muscle Depletion Predicts the Prognosis of Patients with Advanced Pancreatic Cancer Undergoing Palliative Chemotherapy, Independent of Body Mass Index. Co-author DOI 10.1371/journal.pone.0139749↗
  7. Prognostic value of splenic artery invasion in patients undergoing adjuvant chemoradiotherapy after distal pancreatectomy for pancreatic adenocarcinoma. Co-author DOI 10.4143/crt.2014.025↗
  8. The impact of body mass index dynamics on survival of patients with advanced pancreatic cancer receiving chemotherapy. Co-author DOI 10.1016/j.jpainsymman.2013.08.017↗
  9. Phase II clinical trial of induction chemotherapy with fixed dose rate gemcitabine and cisplatin followed by concurrent chemoradiotherapy with capecitabine for… Co-author DOI 10.1007/s00280-012-1918-7↗
  10. Efficacy of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (iFAM) in the treatment of patients with gemcitabine-pretreated pancreatic cancer and analy… Co-author DOI 10.1007/s00280-011-1584-1↗

Trials 2

  1. Fixed Dose Rate Gemcitabine and Cisplatin Followed by Chemoradiation for Locally Advanced Pancreatic Cancer Principal investigator NCT01396668↗
  2. Adjuvant Gemcitabine and Cisplatin Followed by Chemoradiation for Resected Pancreatic Cancer Principal investigator NCT01396681↗

Closest collaborators

The 17 strongest of 17 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yung‐Jue Bang · 10 shared papers, 2011–2021 · strength 0.55
  2. Do‐Youn Oh · 9 shared papers, 2011–2021 · strength 0.52
  3. Kyung-Hun Lee · 6 shared papers, 2011–2021 · strength 0.37
  4. Sung Whan Ha · 5 shared papers, 2012–2021 · strength 0.31
  5. Eui Kyu Chie · 5 shared papers, 2012–2021 · strength 0.31
  6. Younak Choi · 5 shared papers, 2014–2016 · strength 0.27
  7. Jin‐Young Jang · 3 shared papers, 2015–2021 · strength 0.22
  8. Sun‐Whe Kim · 3 shared papers, 2015–2021 · strength 0.22
  9. Kyubo Kim · 3 shared papers, 2015–2016 · strength 0.16
  10. Kim Js · 2 shared papers, 2012–2021 · strength 0.15
  11. Hyunkyung Park · 1 shared paper, 2016 · strength 0.06
  12. Hyeon Kang Koh · 1 shared paper, 2016 · strength 0.06
  13. Ijin Joo · 1 shared paper, 2015 · strength 0.05
  14. Byoung Hyuck Kim · 1 shared paper, 2015 · strength 0.05
  15. Jin‐Hyeok Hwang · 1 shared paper, 2012 · strength 0.03
  16. Yong Bum Yoon · 1 shared paper, 2012 · strength 0.03
  17. Kyu‐Hyoung Lim · 1 shared paper, 2011 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.